To evaluate long‐term outcomes in patients undergoing either paclitaxel‐eluting stents (PES) or endeavor zotarolimus‐eluting stents (E‐ZES) placement and to assess comparative effectiveness of PES vs. E‐ZES in different “off‐label” and… Click to show full abstract
To evaluate long‐term outcomes in patients undergoing either paclitaxel‐eluting stents (PES) or endeavor zotarolimus‐eluting stents (E‐ZES) placement and to assess comparative effectiveness of PES vs. E‐ZES in different “off‐label” and “high‐risk” patient subgroups.
               
Click one of the above tabs to view related content.